An anonymous reader quotes a report from the Conversation: Sound waves at frequencies above the threshold for human hearing are routinely used in medical care. Also known as ultrasound, these sound waves can help clinicians diagnose and monitor disease, and can also provide first glimpses of your newest family members. And now, patients with conditions ranging from cancer to neurodegenerative diseases like Alzheimer's may soon benefit from recent advances in this technology.

I am a biomedical engineer who studies how focused ultrasound -- the concentration of sound energy into a specific volume -- can be fine-tuned to treat various conditions. Over the past few years, this technology has seen significant growth and use in the clinic. And researchers continue to discover new ways to use focused ultrasound to treat disease. [...] Research on focused ultrasound has primarily focused on the most devastating and prevalent diseases, such as cancer and Alzheimer's disease. However, I believe that further developments in, and increased use of, focused ultrasound in the clinic will eventually benefit patients with rare diseases.

One rare disease of particular interest for my lab is cerebral cavernous malformation, or CCM. CCMs are lesions in the brain that occur when the cells that make up blood vessels undergo uncontrolled growth. While uncommon, when these lesions grow and hemorrhage, they can cause debilitating neurological symptoms. The most common treatment for CCM is surgical removal of the brain lesions; however, some CCMs are located in brain areas that are difficult to access, creating a risk of side effects. Radiation is another treatment option, but it, too, can lead to serious adverse effects.

We found that using focused ultrasound to open the blood-brain barrier can improve drug delivery to CCMs. Additionally, we also observed that focused ultrasound treatment itself could stop CCMs from growing in mice, even without administering a drug. While we don't yet understand how focused ultrasound is stabilizing CCMs, abundant research on the safety of using this technique in patients treated for other conditions has allowed neurosurgeons to begin designing clinical trials testing the use of this technique on people with CCM. With further research and advancements, I am hopeful that focused ultrasound can become a viable treatment option for many devastating rare diseases.

Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi received the Nobel Prize in Physiology or Medicine on Monday for their discoveries about how the immune system regulates itself. The three researchers split 11 million Swedish kroner ($1.17 million). Their work identified regulatory T cells and the FOXP3 gene that controls them. Dr. Sakaguchi spent more than a decade solving a puzzle about the thymus. He discovered that the immune system has a backup mechanism to stop harmful cells from attacking the body's own tissues. Dr. Brunkow and Dr. Ramsdell found the specific gene responsible for this process while studying mice that developed severe autoimmune disease.

More than 200 clinical trials are now underway based on their research. Cancers attract regulatory T cells to block immune attacks. Researchers are developing drugs to turn the immune system against these cancer cells. In autoimmune diseases, regulatory T cells are missing or defective. The FOXP3 gene provides a starting point for drugs that teach the immune system to stop attacking itself.

The Wall Street Journal has found "dozens of instances in recent months in which ChatGPT made delusional, false and otherworldly claims to users who appeared to believe them."

For example, "You're not crazy. You're cosmic royalty in human skin..." In one exchange lasting hundreds of queries, ChatGPT confirmed that it is in contact with extraterrestrial beings and said the user was "Starseed" from the planet "Lyra." In another from late July, the chatbot told a user that the Antichrist would unleash a financial apocalypse in the next two months, with biblical giants preparing to emerge from underground...

Experts say the phenomenon occurs when chatbots' engineered tendency to compliment, agree with and tailor itself to users turns into an echo chamber. "Even if your views are fantastical, those are often being affirmed, and in a back and forth they're being amplified," said Hamilton Morrin, a psychiatrist and doctoral fellow at Kings College London who last month co-published a paper on the phenomenon of AI-enabled delusion... The publicly available chats reviewed by the Journal fit the model doctors and support-group organizers have described as delusional, including the validation of pseudoscientific or mystical beliefs over the course of a lengthy conversation... The Journal found the chats by analyzing 96,000 ChatGPT transcripts that were shared online between May 2023 and August 2025. Of those, the Journal reviewed more than 100 that were unusually long, identifying dozens that exhibited delusional characteristics.
AI companies are taking action, the article notes. Monday OpenAI acknowledged there were rare cases when ChatGPT "fell short at recognizing signs of delusion or emotional dependency." (In March OpenAI "hired a clinical psychiatrist to help its safety team," and said Monday it was developing better detection tools and also alerting users to take a break, and "are investing in improving model behavior over time," consulting with mental health experts.)

On Wednesday, AI startup Anthropic said it had changed the base instructions for its Claude chatbot, directing it to "respectfully point out flaws, factual errors, lack of evidence, or lack of clarity" in users' theories "rather than validating them." The company also now tells Claude that if a person appears to be experiencing "mania, psychosis, dissociation or loss of attachment with reality," that it should "avoid reinforcing these beliefs." In response to specific questions from the Journal, an Anthropic spokesperson added that the company regularly conducts safety research and updates accordingly...

"We take these issues extremely seriously," Nick Turley, an OpenAI vice president who heads up ChatGPT, said Wednesday in a briefing to announce the new GPT-5, its most advanced AI model. Turley said the company is consulting with over 90 physicians in more than 30 countries and that GPT-5 has cracked down on instances of sycophancy, where a model blindly agrees with and compliments users.
There's a support/advocacy group called the Human Line Project which "says it has so far collected 59 cases, and some members of the group have found hundreds of examples on Reddit, YouTube and TikTok of people sharing what they said were spiritual and scientific revelations they had with their AI chatbots." The article notes that the group believes "the number of AI delusion cases appears to have been growing in recent months..."

An anonymous reader quotes a report from NBC News: Using brain scans from a very large database, British researchers determined that during the pandemic years of 2021 and 2022, people's brains showed signs of aging, including shrinkage, according to the report published in Nature Communications. People who got infected with the virus also showed deficits in certain cognitive abilities, such as processing speed and mental flexibility. The aging effect "was most pronounced in males and those from more socioeconomically deprived backgrounds," said the study's first author, Ali-Reza Mohammadi-Nejad, a neuroimaging researcher at the University of Nottingham, via email. "It highlights that brain health is not shaped solely by illness, but also by broader life experiences."

Overall, the researchers found a 5.5-month acceleration in aging associated with the pandemic. On average, the difference in brain aging between men and women was small, about 2.5 months. "We don't yet know exactly why, but this fits with other research suggesting that men may be more affected by certain types of stress or health challenges," Mohammadi-Nejad said. [...] The study wasn't designed to pinpoint specific causes. "But it is likely that the cumulative experience of the pandemic -- including psychological stress, social isolation, disruptions in daily life, reduced activity and wellness -- contributed to the observed changes," Mohammadi-Nejad said. "In this sense, the pandemic period itself appears to have left a mark on our brains, even in the absence of infection." "The most intriguing finding in this study is that only those who were infected with SARS-CoV-2 showed any cognitive deficits, despite structural aging," said Jacqueline Becker, a clinical neuropsychologist and assistant professor of medicine at the Icahn School of Medicine at Mount Sinai. "This speaks a little to the effects of the virus itself."

The study may shed light on conditions like long Covid and chronic fatigue, though it's still unclear whether the observed brain changes in uninfected individuals will lead to noticeable effects on brain function.

An anonymous reader quotes a report from The Guardian: Automated surgery could be trialled on humans within a decade, say researchers, after an AI-trained robot armed with tools to cut, clip and grab soft tissue successfully removed pig gall bladders without human help. The robot surgeons were schooled on video footage of human medics conducting operations using organs taken from dead pigs. In an apparent research breakthrough, eight operations were conducted on pig organs with a 100% success rate by a team led by experts at Johns Hopkins University in Baltimore in the US. [...]

The technology allowing robots to handle complex soft tissues such as gallbladders, which release bile to aid digestion, is rooted in the same type of computerized neural networks that underpin widely used artificial intelligence tools such as Chat GPT or Google Gemini. The surgical robots were slightly slower than human doctors but they were less jerky and plotted shorter trajectories between tasks. The robots were also able to repeatedly correct mistakes as they went along, asked for different tools and adapted to anatomical variation, according to a peer-reviewed paper published in the journal Science Robotics. The authors from Johns Hopkins, Stanford and Columbia universities called it "a milestone toward clinical deployment of autonomous surgical systems." [...]

In the Johns Hopkins trial, the robots took just over five minutes to carry out the operation, which required 17 steps including cutting the gallbladder away from its connection to the liver, applying six clips in a specific order and removing the organ. The robots on average corrected course without any human help six times in each operation. "We were able to perform a surgical procedure with a really high level of autonomy," said Axel Krieger, assistant professor of mechanical engineering at Johns Hopkins. "In prior work, we were able to do some surgical tasks like suturing. What we've done here is really a full procedure. We have done this on eight gallbladders, where the robot was able to perform precisely the clipping and cutting step of gallbladder removal without any human intervention. "So I think it's a really big landmark study that such a difficult soft tissue surgery is possible to do autonomously." Currently, nearly all of the NHS's 70,000 annual robotic surgeries are human-controlled, but the UK plans to expand robot-assisted procedures to 90% within the next decade.

Scientists "demonstrated a promising step toward using a person's own immune cells to fight gastrointestinal cancers" at America's National Institutes of Health (or NIH), reports the Washington Post.

But the results were published in Nature Medicine on Tuesday — "the same day the agency was hit with devastating layoffs..." The treatment approach is still early in its development; the personalized immunotherapy regimen shrank tumors in only about a quarter of the patients with colon, rectal and other GI cancers enrolled in a clinical trial. But a researcher who was not involved in the study called the results "remarkable" because they highlight a path to a frustratingly elusive goal in medicine — harnessing a person's own immune defenses to target common solid tumor cancers. Until now, cell-based immunotherapy has worked mainly on blood cancers, such as leukemia, but not the solid cancers that seed tumors in the breast, brain, lungs, pancreas and GI tract...

But the progress arrives at a sad time for science — and for patients, said the leader of the work, NIH immunotherapy pioneer Steven Rosenberg. Two patients' treatments using the experimental therapy had to be delayed because NIH's capacity to make personalized cell therapies has been slowed by the firing of highly skilled staff and by purchasing slowdowns. Those occurred even before major layoffs took place Tuesday... The Department of Health and Human Services (HHS) responded to an email asking about clinical trial delays with a statement: "NIH and HHS are complying with President Trump's executive order."
It's "a very exciting study," said Patrick Hwu, president of the Moffitt Cancer Center in Tampa. Finding ways to tailor this cell-based immunotherapy approach to common solid tumors that cause the vast majority of cancer deaths has remained a major scientific challenge... Rosenberg and colleagues first tried to create tumor infiltrating lymphocytes [or "TILs"] using the method that worked in melanoma for 18 patients with GI cancers that had spread. It failed completely. In a second iteration, his team sequenced the mutations present in each patient's tumor and used that information to sift out and expand the TILs that could home in on that patient's specific tumor cells. The results were far from a triumph, but provided a clue — this time, three of 39 patients' tumors shrank. In the last stage of the trial, the scientists added a drug called pembrolizumab that takes the brakes off immune cells. This time, eight of the 34 patients responded.

"Right now, only a few labs in the country can do what they just did," Hwu said.
While Rosenberg is already working "to refine and improve upon the results," he told the Post that two scientists involved in the specialized process of preparing the cells to treat patients were fired in the probationary purge. "We've had to slow down our work and delay the treatment of some patients...."

And there's also dramatically fewer people now who can purchase research materials, which the Post says it "making it slower and more difficult to obtain supplies."

Stanford University researchers have proposed creating "bodyoids" -- ethically sourced human bodies grown from stem cells without neural components for consciousness or pain sensation -- to revolutionize medical research and address organ shortages. In a new opinion piece published in MIT Technology Review, scientists Carsten T. Charlesworth, Henry T. Greely, and Hiromitsu Nakauchi argue that recent advances in biotechnology make this concept increasingly plausible. The approach would combine pluripotent stem cells, artificial uterus technology, and genetic techniques to inhibit brain development.

The researchers point to persistent shortages of human biological materials as a major bottleneck in medical progress. More than 100,000 patients currently await solid organ transplants in the US alone, while less than 15% of drugs entering clinical trials receive regulatory approval. These lab-grown bodies could potentially generate patient-specific organs that are perfect immunological matches, eliminate the need for lifelong immunosuppression, and provide personalized drug screening models.

A newly FDA-approved form of adaptive deep-brain stimulation (DBS) for Parkinson's disease adjusts electrical stimulation in real time based on an individual's brain signals, improving symptom control and reducing medication dependence. Scientific American: For decades, Keith Krehbiel took high doses of medications with a debilitating side effect -- severe nausea -- following his diagnosis with early-onset Parkinson's disease at age 42 in 1997. When each dose wore off, he experienced dyskinesia -- involuntary, repetitive muscle movements. In his case, this consisted of head bobbing and weaving. Krehbiel is among one million Americans who live with this progressive neurological disorder, which causes slowed movements, tremors and balance problems. But soon after surgery to implant electrodes into specific areas of his brain in 2020, his life dramatically improved. "My tremor went away almost entirely," says Krehbiel, now age 70 and a professor emeritus of political science at the Stanford Graduate School of Business, whose Parkinson's symptoms began at age 40 and were initially misdiagnosed as repetitive stress injury from computer use. "I reduced my Parkinson's meds by more than two thirds," he adds. "And I no longer have a sensation of a foggy brain, nor nausea or dyskinesia."

Krehbiel was the first participant to enroll in a clinical trial testing a new form of deep-brain stimulation (DBS), a technology that gained approval from the U.S. Food and Drug Administration for Parkinson's tremor and essential tremor in 1997 (it was later approved for other symptoms and conditions). The new adaptive system adjusts stimulation levels automatically based on the person's individual brain signals. In late February it received FDA approval for Parkinson's disease "based on results of the international multicenter trial, which involved participants at 10 sites across a total of four countries -- the U.S., the Netherlands, Canada and France. This technology is suitable for anyone with Parkinson's, not just individuals in clinical trials, says Helen Bronte-Stewart, the recent trial's global lead investigator and a neurologist specializing in movement disorders at Stanford Medicine. "Like a cardiac pacemaker that responds to the rhythms of the heart, adaptive deep-brain stimulation uses a person's individual brain signals to control the electric pulses it delivers," Bronte-Stewart says. "This makes it more personalized, precise and efficient than older DBS methods."

"Traditional DBS delivers constant stimulation, which doesn't always match the fluctuating symptoms of Parkinson's disease," adds neurologist Todd Herrington, another of the trial's investigators and director of the deep-brain stimulation program at Massachusetts General Hospital. With adaptive DBS, "the goal is to adjust stimulation in real time to provide more effective symptom control, fewer side effects and improved patient quality of life." Current FDA approval of this adaptive system is for the treatment of Parkinson's only, not essential tremor, dystonia (a neurological disorder that causes excessive, repetitive and involuntary muscle contractions) or epilepsy, which still rely on traditional, continuous DBS, Herrington says.

An anonymous reader quotes a report from The Guardian: A groundbreaking NHS trial will attempt to boost patients' mood using a brain-computer-interface that directly alters brain activity using ultrasound. The device, which is designed to be implanted beneath the skull but outside the brain, maps activity and delivers targeted pulses of ultrasound to "switch on" clusters of neurons. Its safety and tolerability will be tested on about 30 patient in the 6.5 million-pound trial, funded by the UK's Advanced Research and Invention Agency (Aria).

[...] The latest trial will test a device developed by the US-based non-profit Forest Neurotech. In contrast to invasive implants, in which electrodes are inserted into a specific location in the brain, Forest 1 uses ultrasound to read-out and modify activity. Aria describes the device as "the most advanced BCI in the world" due to its ability to modify activity across multiple regions simultaneously. This widens potential future applications to a huge patient population affected by conditions such as depression, anxiety and epilepsy, which are all "circuit level" conditions rather than being localized in a specific brain region.

The NHS trial will recruit patients who, due to brain injury, have had part of their skull temporarily removed to relieve a critical buildup of pressure in the brain. This means the device can be tested without having to perform surgery. When placed beneath the skull, or in individuals with a skull defect, ultrasound can detect tiny changes in blood flow to produce 3D maps of brain activity with a spatial resolution of about 100 times that of a typical fMRI scan. The same implant can deliver focused ultrasound to mechanically nudge neurons towards firing, providing a way to remotely dial activity up at precise locations. Participants will wear the device on their scalp at the site of the skull defect for two hours. Their brain activity will be measured and researchers will test whether patients' mood and feelings of motivation can be reliably altered.

There are safety considerations, as ultrasound can cause tissue to heat up. Prof Elsa Fouragnan, a neuroscientist at the University of Plymouth, which is collaborating on the project, said: "What we're trying to minimize is heat. There's a safety and efficacy trade-off." She added that it would also be important to ensure that personality or decision-making were not altered in unintended ways -- for instance, making someone more impulsive. The study will run for three and a half years starting from March, with the first eight months focused on securing regulatory approval. If successful, Forest hopes to move into a full clinical trial for a condition such as depression. Aimun Jamjoom, a consultant neurosurgeon at the Barking, Havering and Redbridge university hospitals NHS trust, who is leading the project, said: "[T]he ability to offer a safer form of surgery is very exciting. If you look at conditions like depression or epilepsy, [up to] a third of these patients just don't get better. It's those groups where a technology like this could be a life-changing solution."

Our bodies divest themselves of 60 billion cells every day through a natural process called "apoptosis". So Stanford medicine researchers are developing a new approach to cancer therapy that could "trick cancer cells into disposing of themselves," according to announcement from Stanford's medical school: Their method accomplishes this by artificially bringing together two proteins in such a way that the new compound switches on a set of cell death genes... One of these proteins, BCL6, when mutated, drives the blood cancer known as diffuse large cell B-cell lymphoma... [It] sits on DNA near apoptosis-promoting genes and keeps them switched off, helping the cancer cells retain their signature immortality.

The researchers developed a molecule that tethers BCL6 to a protein known as CDK9, which acts as an enzyme that catalyzes gene activation, in this case, switching on the set of apoptosis genes that BCL6 normally keeps off. "The idea is, Can you turn a cancer dependency into a cancer-killing signal?" asked Nathanael Gray, PhD, co-senior author with Crabtree, the Krishnan-Shah Family Professor and a chemical and systems biology professor. "You take something that the cancer is addicted to for its survival and you flip the script and make that be the very thing that kills it...."

When the team tested the molecule in diffuse large cell B-cell lymphoma cells in the lab, they found that it indeed killed the cancer cells with high potency. They also tested the molecule in healthy mice and found no obvious toxic side effects, even though the molecule killed off a specific category of of the animals' healthy B cells, a kind of immune cell, which also depend on BCL6. They're now testing the compound in mice with diffuse large B-cell lymphoma to gauge its ability to kill cancer in a living animal. Because the technique relies on the cells' natural supply of BCL6 and CDK9 proteins, it seems to be very specific for the lymphoma cells — the BCL6 protein is found only in this kind of lymphoma cell and in one specific kind of B cell. The researchers tested the molecule in 859 different kinds of cancer cells in the lab; the chimeric compound killed only diffuse large cell B-cell lymphoma cells.
Scientists have been trying to shut down cancer-driving proteins, one of the researchers says, but instead, "we're trying to use them to turn signaling on that, we hope, will prove beneficial for treatment."

The two researchers have co-founded the biotech startup Shenandoah Therapeutics, which "aims to further test this molecule and a similar, previously developed molecule," according to the article, "in hopes of gathering enough pre-clinical data to support launching clinical trials of the compounds.

"They also plan to build similar molecules that could target other cancer-driving proteins..."

An anonymous reader quotes a report from The Verge: The Senate passed the Kids Online Safety Act (KOSA) and the Children and Teens' Online Privacy Protection Act (also known as COPPA 2.0), the first major internet bills meant to protect children to reach that milestone in two decades. A legislative vehicle that included both KOSA and COPPA 2.0 passed 91-3. Senate Majority Leader Chuck Schumer (D-NY) called it "a momentous day" in a speech ahead of the vote, saying that "the Senate keeps its promise to every parent who's lost a child because of the risks of social media." He called for the House to pass the bills "as soon as they can."

KOSA is a landmark piece of legislation that a persistent group of parent advocates played a key role in pushing forward -- meeting with lawmakers, showing up at hearings with tech CEOs, and bringing along photos of their children, who, in many cases, died by suicide after experiencing cyberbullying or other harms from social media. These parents say that a bill like KOSA could have saved their own children from suffering and hope it will do the same for other children. The bill works by creating a duty of care for online platforms that are used by minors, requiring they take "reasonable" measures in how they design their products to mitigate a list of harms, including online bullying, sexual exploitation, drug promotion, and eating disorders. It specifies that the bill doesn't prevent platforms from letting minors search for any specific content or providing resources to mitigate any of the listed harms, "including evidence-informed information and clinical resources." The legislation faces significant opposition from digital rights, free speech, and LGBTQ+ advocates who fear it could lead to censorship and privacy issues. Critics argue that the duty of care may result in aggressive content filtering and mandatory age verification, potentially blocking important educational and lifesaving content.

The bill may also face legal challenges from tech platforms citing First Amendment violations.

Researchers have made significant progress toward developing a blood test that can predict the risk of dementia up to 15 years before clinical diagnosis. The Guardian reports: Hopes for the test were raised after scientists discovered biological markers for the condition in blood samples collected from more than 50,000 healthy volunteers enrolled in the UK Biobank project. Analysis of the blood identified patterns of four proteins that predicted the onset of dementia in general, and Alzheimer's disease and vascular dementia specifically, in older age. When combined with more conventional risk factors such as age, sex, education and genetic susceptibility, the protein profiles allowed researchers to predict dementia with an estimated 90% accuracy nearly 15 years before people received clinical confirmation of the disease.

For the latest study, blood samples from 52,645 UK adults without dementia were collected and frozen between 2006 and 2010 and analyzed 10 to 15 years later. More than 1,400 participants went on to develop dementia. Using artificial intelligence, the researchers looked for connections between nearly 1,500 blood proteins and developing dementia years later. Writing in Nature Aging, they describe how four proteins, Gfap, Nefl, Gdf15 and Ltbp2, were present in unusual levels among those who developed all-cause dementia, Alzheimer's disease or vascular dementia. Higher levels of the proteins were warning signs of disease. Inflammation in the brain can trigger cells called astrocytes to over-produce Gfap, a known biomarker for Alzheimer's. People with raised Gfap were more than twice as likely to develop dementia than those with lower levels.

Another blood protein, Nefl, is linked to nerve fibre damage, while higher than normal Gdf15 can occur after damage to the brain's blood vessels. Rising levels of Gfap and Ltbp2 was highly specific for dementia rather than other brain diseases, the scientists found, with changes occurring at least 10 years before people received a dementia diagnosis. The researchers are speaking to companies to develop the test but said the cost, currently at several hundred pounds, would need to come down to make it viable.

The Seattle Times reports: Concerns have grown in recent weeks about data privacy and the ongoing impacts of a recent Fred Hutchinson Cancer Center cyberattack that leaked personal information of about 1 million patients last November. Since the breach, which hit the South Lake Union cancer research center's clinical network and has led to a host of email threats from hackers and lawsuits against Fred Hutch, menacing messages from perpetrators have escalated.

Some patients have started to receive "swatting" threats, in addition to spam emails warning people that unless they pay a fee, their names, Social Security and phone numbers, medical history, lab results and insurance history will be sold to data brokers and on black markets. Steve Bernd, a spokesperson for FBI Seattle, said last week there's been no indication of any criminal swatting events... Other patients have been inundated with spam emails since the breach...

According to The New York Times, large data breaches like this are becoming more common. In the first 10 months of 2023, more than 88 million individuals had their medical data exposed, according to the Department of Health and Human Services. Meanwhile, the number of reported ransomware incidents, when a specific malware blocks a victim's personal data until a ransom is paid, has decreased in recent years — from 516 in 2021 to 423 in 2023, according to Bernd of FBI Seattle. In Washington, the number dropped from 84 to 54 in the past three years, according to FBI data.
Fred Hutchinson Cancer Center believes their breach was perpetrated outside the U.S. by exploiting the "Citrix Bleed" vulnerability (which federal cybersecurity officials warn can allow the bypassing of passwords and mutifactor authentication measures).

The article adds that in late November, the Department of Health and Human Services' Health Sector Cybersecurity Coordination Center "urged hospitals and other organizations that used Citrix to take immediate action to patch network systems in order to protect against potentially significant ransomware threats."

Researchers from several U.S. institutions are collaborating "to develop and test an implantable device able to sense signs of the kind of inflammation associated with cancer," reports CBS News, "and delivery therapy when needed." Northwestern said the implant could significantly improve outcomes for patients with ovarian, pancreatic and other difficult-to-treat cancers — potentially cutting cancer-related deaths in the U.S. in half. "Instead of tethering patients to hospital beds, IV bags and external monitors, we'll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time," said Rice University bioengineer Omid Veiseh. "This kind of 'closed-loop therapy' has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it's revolutionary."
The project and team are named THOR, an acronym for "targeted hybrid oncotherapeutic regulation..." explains an announcement from Johns Hopkins. "THOR's proposed implant, or 'hybrid advanced molecular manufacturing regulator,' goes by the acronym HAMMR..."

The project will take five and a half years, and includes funding for a first-phase clinical trial treating recurrent ovarian cancer slated to begin in the fourth year. The research is funded by America's newly-established Advanced Research Projects Agency for Health (ARPA-H), according to a statement from the agency, representing its "commitment to supporting Cancer Moonshot goals of decreasing cancer deaths and improving the quality of life for patients..."

And they're also funding two more projects: The Synthetic Programmable bacteria for Immune-directed Killing in tumor Environments (SPIKEs) project, led by a team at the University of Missouri in Columbia, Missouri, aims to develop an inexpensive and safe therapy using bacteria specifically selected for tumor-targeting. Through SPIKEs, researchers intend to engineer bacteria that can recruit and regulate tumor-targeting immune cells, boosting the body's ability to fight off cancer without side-effects from traditional medications. Up to $19 million is allocated towards SPIKEs.

An additional project, with up to $50 million in potential funding inclusive of options, seeks to map cancer cell biomarkers to drastically improve multi-cancer early detection (MCED) and streamline clinical intervention when tumors are still small. Led by the Georgia Institute of Technology in Atlanta, Georgia, the Cancer and Organ Degradome Atlas (CODA) project aims to understand the cellular profiles unique to diseased cancer cells. The CODA platform intends to develop a suite of biosensor tools that can reliably recognize a range of cancer-specific markers and, ultimately, produce a highly precise, accurate, and cost-effective MCED test that can identify common cancers when they are most treatable.
In a statement, ARPA-H's director said that "With these awards, we hope to see crucial advancements in patient-tailored therapies, better and earlier tumor detection methods, and cell therapies that can help the immune system target cancer cells for destruction."

Elad Gil, writing in a blog post: In most industries, regulation prevents competition. This famous chart of prices over time reflects how highly regulated industries (healthcare, education, energy) have their costs driven up over time, while less regulated industries (clothing, software, toys) drop costs dramatically over time. (Please note I do not believe these are inflation adjusted - so 60-70% may be "break even" pricing inflation adjusted.)

Regulation favors incumbents in two ways. First, it increase the cost of entering a market, in some cases dramatically. The high cost of clinical trials and the extra hurdles put in place to launch a drug are good examples of this. A must-watch video is this one with Paul Janssen, one of the giants of pharma, in which he states that the vast majority of drug development budgets are wasted on tests imposed by regulators which "has little to do with actual research or actual development." This is a partial explanation for why (outside of Moderna, an accident of COVID), no $40B+ market cap new biopharma company has been launched in almost 40 years (despite healthcare being 20% of US GDP).

Secondly, regulation favors incumbents via something known as "regulatory capture." In regulatory capture, the regulators become beholden to a specific industry lobby or group -- for example by receiving jobs in the industry after working as a regulator, or via specific forms of lobbying. There becomes a strong incentive to "play nice" with the incumbents by regulators and to bias regulations their way, in order to get favors later in life. Additional resource: All-In Summit: Bill Gurley Presents 2,851 Miles.

An anonymous reader quotes a report from Ars Technica: On Monday, Microsoft and Epic Systems announced that they are bringing OpenAI's GPT-4 AI language model into health care for use in drafting message responses from health care workers to patients and for use in analyzing medical records while looking for trends. Epic Systems is one of America's largest health care software companies. Its electronic health records (EHR) software (such as MyChart) is reportedly used in over 29 percent of acute hospitals in the United States, and over 305 million patients have an electronic record in Epic worldwide. Tangentially, Epic's history of using predictive algorithms in health care has attracted some criticism in the past.

In Monday's announcement, Microsoft mentions two specific ways Epic will use its Azure OpenAI Service, which provides API access to OpenAI's large language models (LLMs), such as GPT-3 and GPT-4. In layperson's terms, it means that companies can hire Microsoft to provide generative AI services for them using Microsoft's Azure cloud platform. The first use of GPT-4 comes in the form of allowing doctors and health care workers to automatically draft message responses to patients. The press release quotes Chero Goswami, chief information officer at UW Health in Wisconsin, as saying, "Integrating generative AI into some of our daily workflows will increase productivity for many of our providers, allowing them to focus on the clinical duties that truly require their attention." The second use will bring natural language queries and "data analysis" to SlicerDicer, which is Epic's data-exploration tool that allows searches across large numbers of patients to identify trends that could be useful for making new discoveries or for financial reasons. According to Microsoft, that will help "clinical leaders explore data in a conversational and intuitive way." Imagine talking to a chatbot similar to ChatGPT and asking it questions about trends in patient medical records, and you might get the picture. Dr. Margaret Mitchell, chief ethics scientist at Hugging Face, is concerned about GPT-4's ability to make up information that isn't represented in its data set. Another concern is the potential bias in GPT-4 that might discriminate against certain patients based on gender, race, age, or other factors.

"Combined with the well-known problem of automation bias, where even experts will believe things that are incorrect if they're generated automatically by a system, this work will foreseeably generate false information," says Mitchell. "In the clinical setting, this can mean the difference between life and death."

An anonymous reader shares a report: Deep brain stimulation is already used to treat severe cases of epilepsy and a few movement disorders such as Parkinson's. But depression is more complicated -- partly because we still don't fully understand what's going on in the brain when it occurs. "Depression is a complex illness," says Patricio Riva Posse, a neurologist at the Emory School of Medicine in Atlanta, Georgia, who was not involved in the trial. "It's not like trying to correct one tremor -- there's a whole universe of symptoms." These include low mood, suicidality, inability to experience pleasure, and changes in motivation, sleep, and appetite.

Doctors have been using electricity to treat brain disorders -- including depression -- for decades, and some studies have found that electrodes placed deep inside the brain can jolt some people out of their symptoms. But results vary. Neuroscientists hope that by getting a better idea of what's happening inside the brains of people with symptoms like John's, they can make the treatment more effective. John is one of five people who have volunteered to have their brains probed as part of a clinical trial. At the start of 2020, he had a total of 14 electrodes implanted across his brain. For nine days, he stayed in a hospital with protruding cables wrapped around his head, while neuroscientists monitored how his brain activity correlated with his mood.

The researchers behind the trial say they have developed a "mood decoder" -- a way of being able to work out how someone is feeling just by looking at brain activity. Using the decoder, the scientists hope to be able to measure how severe a person's depression is, and target more precisely where the electrodes are placed to optimize the effect on the patient's mood. So far, they have analyzed the results of three volunteers. What they have found is extremely promising, says Sameer Sheth, a neurosurgeon based at Baylor College of Medicine in Houston, Texas, who is leading the trial. Not only have he and his colleagues been able to link volunteers' specific brain activity with their mood, but they have also found a way to stimulate a positive mood. "This is the first demonstration of successful and consistent mood decoding of humans in these brain regions," says Sheth. His colleague Jiayang Xiao presented the findings at the Society for Neuroscience's annual meeting in San Diego in November.

A small clinical trial has shown that researchers can use CRISPR gene editing to alter immune cells so that they will recognize mutated proteins specific to a person's tumours. Those cells can then be safely set loose in the body to find and destroy their target. It is the first attempt to combine two hot areas in cancer research: gene editing to create personalized treatments, and engineering immune cells called T cells so as to better target tumours. From a report: The approach was tested in 16 people with solid tumours, including in the breast and colon. "It is probably the most complicated therapy ever attempted in the clinic," says study co-author Antoni Ribas, a cancer researcher and physician at the University of California, Los Angeles. "We're trying to make an army out of a patient's own T cells." The results were published in Nature and presented at the Society for Immunotherapy of Cancer meeting in Boston, Massachusetts on 10 November.

Ribas and his colleagues began by sequencing DNA from blood samples and tumour biopsies, to look for mutations that are found in the tumour but not in the blood. This had to be done for each person in the trial. "The mutations are different in every cancer," says Ribas. "And although there are some shared mutations, they are the minority." The researchers then used algorithms to predict which of the mutations were likely to be capable of provoking a response from T cells, a type of white blood cell that patrols the body looking for errant cells. "If [T cells] see something that looks not normal, they kill it," says Stephanie Mandl, chief scientific officer at PACT Pharma in South San Francisco, California, and a lead author on the study. "But in the patients we see in the clinic with cancer, at some point the immune system kind of lost the battle and the tumour grew." After a series of analyses to confirm their findings, validate their predictions and design proteins called T-cell receptors that are capable of recognizing the tumour mutations, the researchers took blood samples from each participant and used CRISPR genome editing to insert the receptors into their T cells.

Diana Kwon writes via Scientific American: A Scottish woman named Joy Milne made headlines in 2015 for an unusual talent: her ability to sniff out people afflicted with Parkinson's disease, a progressive neurodegenerative illness that is estimated to affect nearly a million people in the U.S. alone. Since then a group of scientists in the U.K. has been working with Milne to pinpoint the molecules that give Parkinson's its distinct olfactory signature. The team has now zeroed in on a set of molecules specific to the disease -- and has created a simple skin-swab-based test to detect them.

[...] The researchers used mass spectrometry to identify types and quantities of molecules in a sample of sebum, an oily substance found on the skin's surface. They discovered changes to fatty molecules known as lipids in people with Parkinson's. In their latest study, published on September 7 in the American Chemical Society journal JACS Au, the researchers revealed the results of using a simple skin-swab-based test to detect the lipid signature that is indicative of Parkinson's. By comparing sebum samples from 79 people with Parkinson's and 71 people without the illness, the team zeroed in on a set of large lipids that could be detected in a matter of minutes using a special type of mass spectrometry in which substances are rapidly transferred from a swab to an analyzer using just a piece of paper.

"I think it's a very promising set of biomarkers," says Blaine Roberts, a biochemist at Emory University, who wasn't involved in the work. He adds that one of the big open questions that remains is how exacting this test can be. While the authors of the September 7 study reported the detailed chemical profile of the unique Parkinson's signature, they did not include an assessment of its accuracy. According to Barran, based on not-yet-published data, their test appears to be able to determine whether an individual has Parkinson's with more than 90 percent accuracy. [...] The team is now working with local hospitals to determine whether this sebum-based test can also be conducted in clinical labs -- a key step toward determining whether it can be used as a diagnostic tool. Ultimately, Barran says, the hope is to use the test to help identify individuals who have been referred to their neurologists by their general practitioner for suspected Parkinson's so they can receive a faster diagnosis. The researchers are also working with a group at Harvard "to determine whether sebum-based biomarkers are detectable in people who have constipation, a reduced sense of smell or other early signs of Parkinson's but have not yet received a diagnosis," reports Kwon.

Meanwhile, Milne is working with scientists to sniff out people with Alzheimer's, cancer, and tuberculosis -- all of which she says have a unique smell.

The short answers are "yes" and "no." America's Constitution prohibits government intervention into public expression, reports the business-news radio show Marketplace, "protecting free speech and expression "through, for example.... writing, protesting and coding languages like JavaScript, HTML, Python and Perl."

Specifically protecting code started with the 1995 case of cryptographer Daniel Bernstein, who challenged America's "export controls" on encryption (which regulated it like a weapon). But they also spoke to technology lawyer Kendra Albert, a clinical instructor at Harvard Law School's Cyberlaw Clinic, about the specific parameters of how America protects code as a form of expression: Albert: I think that the reality was that the position that code was a form of expression is in fact supported by a long history of First Amendment law. And that it, you know, is very consistent with how we see the First Amendment interpreted across a variety of contexts.... [O]ne of the questions courts ask is whether a regulation or legislation or a government action is specifically targeting speech, or whether the restrictions on speech are incidental, but not the overall intention. And that's actually one of the places you see kind of a lot of these difficulties around code as speech. The nature of many kinds of regulation may mean that they restrict code because of the things that particular forms of software code do in the world. But they weren't specifically meant to restrict the expressive conduct. And courts end up then having to sort of go through a test that was originally developed in the context of someone burning a draft card to figure out — OK, is this regulation, is the burden that it has on this form of expressive speech so significant that we can't regulate in this way? Or is this just not the focus, and the fact that there are some restrictions on speech as a result of the government attempting to regulate something else should not be the focus of the analysis?

Q: Congress and federal agencies as well as some states are looking to tighten regulations around cryptocurrencies and blockchain technology. What role do you think the idea of code as speech will play in this environment moving forward?

Albert: The reality is that the First Amendment is not a total bar to regulation of speech. It requires the government meet a higher standard for regulating certain kinds of speech. That runs, to some extent, in conflict with how people imagine what "code is speech" does as sort of a total restriction on the regulation of software, of code, because it has expressive content. It just means that we treat code similarly to how we treat other forms of expression, and that the government can regulate them under certain circumstances.